

July 1991 to June 1993	Fellow, Division of Child and Adolescent Psychiatry University of Texas Medical School, Houston, Texas
July 1988 to June 1991	Resident, Department of Psychiatry, University of Texas Medical School, Houston, Texas
September 1987 June 1988	Post Doctoral Fellow, in Geriatric Research Psychiatry, University of Texas Mental Sciences Institute, Houston, Texas

AWARDS:

- Appointed, Co-Chair, US Psych Congress Annual Meetings. 2015, 2016, 2017, 2022, 2023, 2024
- Appointed, Co-Chair, Nurse Practitioner Institute National Meeting (NP Institute), 2023
- Appointed, Steering Committee, Elevate Psychiatry CME Annual Meeting. 2021, 2022, 2023, 2024
- Appointed, Steering Committee, Sana Psychedelic Symposium. 2021, 2022, 2023
- Awarded the “US Psychiatric Congress Host for the 2010 Meeting” by the United States Psychiatric Annual Meeting, Orlando, Florida, 2010
- Awarded the “US Psychiatric Congress Teacher of the Year Award”, by the United States Psychiatric Congress Annual Meeting, San Diego, California, 2008
- Awarded the “Extra Mile Award”, by the Faculty and Students of Brazosport Independent School District (BISD), Lake Jackson, Texas, in recognition of educational and consulting services provided that were above and beyond the call of duty, 2007
- Awarded “Public Citizen of the Year”, by the National Association of Social Workers, Gulf Coast Chapter, Texas, for the year 2001, in recognition of Community and Peer education and championing mental health issues.
- Recipient of National Research Service Award for the support of the Post Doctoral Fellowship, awarded through the Gerontology Center, University of Texas Mental Sciences Institute, Houston, Texas 1987 to 1988
- Awarded the National Institute/Center for Disease Control Competitive Traineeship through the University of Texas School of Public Health, Houston, Texas 1986-1987

- Awarded the Dr. B.C. Roy Memorial Scholarship for academic excellence as medical student, Calcutta University, India. 1985

BOOK AUTHORSHIP:

“The Science and Practice of Wellness: Interventions for Happiness, Enthusiasm, Resilience, and Optimism (HERO). Rakesh Jain, Saundra Jain. Norton Publishing, 2020. ISBN-13: 978-0393713657

“WILD 5 Wellness KickStart30: A Proven 30-Day Mental Wellness Program.” Saundra Jain, Rakesh Jain, Betsy Burns. 2019. ISBN: 9781791658809

“WILD 5 Wellness LiveWell90: A Proven 90-Day Mental Wellness Program.” Saundra Jain, Rakesh Jain, Betsy Burns. 2019. ISBN: 978179210833

“In the Clinic-Understanding the Impact of Cognitive Impairment on Patients’ Daily Lives”. Henry Nasarallah, Richard Keefe, Grey Mattingly, Alan Schatzberg, Rakesh Jain, Dawn Velligan. 2016. eBook, Posted on Apple iBooks and GooglePlay stores

“Integrating the Mind-Body Connection into Mental Health Care”. Jon Draud, MD, Rakesh Jain, MD, Vlad Maletic, Chuck Raison, MD. Publisher – CME LLC. 2011

“Unleashed: Transforming My Battle With Depression”. Saundra Jain, PsyD, Rakesh Jain, MD. Published by Create Space, ISBN #1461014816. 2011

“Unleashed: 12-Weeks to Total Mental Fitness: Workbook to Optimize Your Mental Health”. Saundra Jain, PsyD, Rakesh Jain and MD. Published by Create Space, ISBN #1466269057. 2011

“Mind-Body Depression: A New Look at an Old Nemesis”. Charles Raison, MD, Vladimir Maletic, MD, Rakesh Jain, MD. Manuscript in development. Under contract with Norton Professional Books, New York, NY

100 Questions on Pain- A patient Guidebook. Rakesh Jain, MD,, MPH, Vlad Maletic, MD, Chuck Raison, MD. Jones and Barlett Publishers, New York

50 Affirmations for People Who Choose to Take Medications for Depression. Saundra Jain, PsyD, Rakesh Jain, MD, MPH. 3 Cool Cats Publications, 2001. Book ISBN # 0-971343-0-8

PUBLICATIONS:

Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled posthoc analysis. Rakesh Jain, Roger S. McIntyre, Andrew J. Cutler, et al. *International Clinical Psychopharmacology* 2024, 39:82–92

Treatment patterns, health care resource utilization, and costs associated with use of atypical antipsychotics as first vs subsequent adjunctive treatment in major depressive disorder. Rakesh Jain, MD, MPH; François Laliberté, MA; Guillaume Germain, MSc; Malena Mahendran, MSc; Sara Higa, PharmD, MS; Amanda Harrington, PhD; Mousam Parikh, MS. *J Manag Care Spec Pharm.* 29(8):896-906. 2023

New Developments in the Treatment of Schizophrenia: An Expert Roundtable. Joshua T. Kantrowitz, Christoph U. Correll, Rakesh Jain, Andrew J. Cutler. *International Journal of Neuropsychopharmacology*, 26, (322-330). 2023

Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States. Zachary Herrmann, Adam W. Levin, Steven P. Cole, Sarah Slabaugh, Brian Barnett, Andrew Penn, Rakesh Jain, Charles Raison, Bhavya Rajanna, and Saundra Jain. *Psychedelic Medicine* Volume 1, Number 3. 2023

“Digital health technologies and major depressive disorder.” Roger S. McIntyre, Walter Greenleaf, Grzegorz Bulaj, Steven T. Taylor, Georgia Mitsi, Dylan Saliu, Andy Czysz, Greg Silvesti, Manny Garcia and Rakesh Jain. *CNS Spectrum*. 2023

Improvement of Mental Health Symptoms in Response to Ketamine Therapy in Medicaid-Eligible Patients. Carl J Bonnett, Jasmine Bonder, Rakesh Jain, Andrew Stabbert' and Casey Sayre. *Journal of Psychiatry and Mental Health*, 2023

A 30-day adjunct wellness intervention for the management of extra-articular symptoms of rheumatoid arthritis: A formative study. Hutson, T., Murman, N., Rolin, D., Jain, R., Laster, A.J., Cole, S.P., & Jain, S. (2022). *Journal of Evidence-Based Integrative Medicine*. 2022.

Treatment Patterns During Major Depressive Episodes Among Patients with Major Depressive Disorder: A Retrospective Database Analysis. Jain R, Higa S, Keyloun K, Park J. Bonafede M, Tung A, Gillard P, Cutler AJ. *Drugs - Real World Outcomes* <https://doi.org/10.1007/s40801-022-00316-4>, 2022

Treatment Patterns Among Patients with Bipolar Disorder in the United States: A Retrospective Claims Database Analysis. Jain R, Kong AM, Gillard P, Harrington A. *Adv Ther.* 2022 Jun;39(6):2578-2595. doi: 10.1007/s12325-022-02112-6. Epub 2022 Apr 6.

Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States. Raison CL, Jain R, Penn AD, Cole SP, Jain S. *Front Psychiatry* 2022. Mar 15;13:831092

Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder. Chepke C, Jain R, Rosenberg R, Moline M, Yardley J, Pinner K, Kumar D, Perdomo C, Filippov G, Atkins N, Malhotra M. *Postgrad Med* 2022. Apr; 134(3):316-325

The Rapid Mood Screener (RMS): a novel and pragmatic screener for bipolar I disorder McIntyre RS, Patel MD, Masand PS, Harrington A, Gillard P, McElroy SL, Sullivan K, Montano CB, Brown TM, Nelson L, Jain R. *Curr Med Res Opin* 2021. Jan;37(1):135-144

Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies. Patel M, Jain R, Tohen M, Maletic V, Earley WR, Yatham LN. *Int Clin Psychopharmacol*. 2021. Mar 1;36(2):76-83

Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. Cutler AJ, Mattingly GW, Jain R, O'Neal W. *CNS Spectr*. 2022. Apr;27(2):199-207

“The Broad Efficacy of Cariprazine Across Symptoms in Patients With Bipolar I Disorder: Post Hoc Analysis of Randomized, Placebo-Controlled Trials”. Lakshmi Yatham, Eduard Vieta, Roger S. McIntyre, Rakesh Jain, Willie Earley, Mehul Patel. *CNS Spectrum* 2020. Apr;25(2):300. doi: [10.1017/S1092852920000723](https://doi.org/10.1017/S1092852920000723).

“A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia”. San Caroff, Leslie Citrome, Jonathan Meyer, Martha Sajatovic, Joseph P Goldberg, Rakesh Jain, et al. *J Clin Psychiatry* 2020. Jan 28;81(2): [19cs12983](https://doi.org/10.4088/JCP.19cs12983).doi: [10.4088/JCP.19cs12983](https://doi.org/10.4088/JCP.19cs12983).

“HERO Wellness Scale: Examining a New Mental Wellness Scale”. Sandy Yakin, Rakesh Jain, Steve Cole, Charles Raison, Donna Rolin, Sandra Jain. *Annals of Clinical Psychiatry* 2020. Feb;32(1):33-40

“Good, Better, Best – clinical scenarios for the use of L-methylfolate in patients with MDD”. Rakesh Jain , Sloan Manning, Andrew Cutler. *CNS Spectrum*. 2019. Dec 13:1-15. *CNS Spectr*. 2019 Dec 13:1-15. doi: [10.1017/S1092852919001469](https://doi.org/10.1017/S1092852919001469).

“Wellness Interventions in Psychiatrically Ill Patients: Impact of WILD 5 Wellness, a Five-Domain Mental Health Wellness Intervention on Depression, Anxiety, and Wellness.” Donna Rolin, Isadora Fox , Rakesh Jain, Steve P Cole, Cecelia Tran, Sandra Jain. *Am Psychiatr Nurses Assoc*. 2019 Nov 18: doi: [10.1177/1078390319886883](https://doi.org/10.1177/1078390319886883).

High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. Cassie Ross, Rakesh Jain, Carl J Bonnett, Paul Wolfson. *Ann Clin Psychiatry*. 2019 Nov;31(4):271-279.

“Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia.” Rakesh Jain, Jonathan Meyer , A Wehr, B Rege , L von Moltke, Peter Weiden. *CNS Spectr*. 2020 Jun;25(3):323-330. doi: 10.1017/S1092852919000816.

“Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis”. Rakesh Jain, Christoff Correll. *J Clin Psychiatry*. 2018 Mar/Apr;79(2):nu17034ah1c. doi: 10.4088/JCP.nu17034ah1c

“The Odd Couple?-Hardly.” Editorial. Peter Taylor, Rakesh Jain. *Rheumatology (Oxford)*. 2018 Aug 1;57(8):1313-1315. doi: 10.1093/rheumatology/kex205

“Addressing Diagnosis and Treatment Gaps in Adults With Attention-Deficit/Hyperactivity Disorder.” Rakesh Jain, Saundra Jain , Brandon Montano. *Prim Care Companion CNS Disord*. 2017 Sep 7;19(5):17nr02153. doi: 10.4088/PCC.17nr02153.

“Current and Investigational Medication Delivery Systems for Treating Attention-Deficit Hyperactivity Disorder.” Rakesh Jain, Alain Katic. *Prim Care Companion CNS Disord*. Aug 18;18(4), 2016

“The identification and resolution of residual symptoms in depressed primary care patients.” Rakesh Jain. *J Clin Psychiatry*. Jan;77(1):e33. doi: 10.4088/JCP.14061tx6c. 2016

“Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications.” Rakesh Jain, JG Stark. *Postgrad Med*.;128(7):672-81. 2016.

“Improving adherence in primary care patients with depression.” Rakesh Jain, William Jackson, Brandon Montano. *Journal of Clinical Psychiatry*. December 2015

“Saving time with measurement-based care for depression in primary care.” Rakesh Jain, William Jackson, Brandon Montano. *Journal of Clinical Psychiatry*. October 2015

“Efficacy and Safety of Low Field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression”. Andrew Leucter, Ian Cook, David Feifel, John Goeth, Linda Carpenter, Michael Thase, Andrew Crystalm Noah Phillips, William Burke, Yvette Sheline, Scott Aaronson, Rakesh Jain, Bill Phillips, Sarah Lisanby, Mark S. George. *Brain Stimulation*. 2015.

“Cognitive Impairment in Schizophrenia –Understanding the Neurobiology and Its Implications for the Future Management”. Stephan Marder, Peter Weiden, Anissa Dargham, Rona Hu, Alex Kopelwix, Afzar Malik, Sheldon Preskorn, Gus Alva, Rakesh Jain, Greg Mattingly, Vlad Maletic, Steven Potkin and the others members of the work group. *Current Psychiatry*. January 2015.

“An Overview of Vortioxetine: Alan Schatzberg, Pier Blier, Larry Culpepper, Rakesh Jain, George Papakostas, Michael Thase. *Journal of Clinical Psychiatry*. December 2014

“Cognitive Impairment and Poor Functional Outcomes in Schizophrenia”. Anil Malhotra, Stephan Marder, Peter Weiden, Anissa Dargham, Rona Hu, Alex Kopelwix, Afzar Malik, Sheldon Preskorn, Gus Alva, Rakesh Jain, Greg Mattingly, Vlad Maletic, Steven Potkin and the others members of the work group. *Current Psychiatry*. December 2014.

“Cognitive Impairment in Schizophrenia – Understanding Prevalence, Magnitude, and Scope” Anil Malhotra, Stephan Marder, Peter weiden, Anissa Dargham, Rona Hu, Alex Kopelwix, Afzar Malik, Sheldon Preskorn, Gus Alva, Rakesh Jain, Greg Mattingly, Vlad Maletic, Steven Potkin and the others members of the work group. *Current Psychiatry*. November 2014.

“Be prepared to adjust the dosing of psychotropics after bariatric surgery”. Shailesh Jain, MD, Rakesh Jain, MD. *Current Psychiatry*. October 2014

“Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.” Cook IA, Hunter AM, Gilmer WS, Iosifescu DV, Zisook S, Burgoyne KS, Howland RH, Trivedi MH, Jain R, Greenwald S, Leuchter AF. *J Clin Psychiatry*. 2013 Jan;74(1):51-6. doi: 10.4088/JCP.10m06813

“What to tell children after a school shooting – 8 tips”. Shailesh Jain, MD, Rakesh Jain, MD. *Current Psychiatry*. Vol 12. No 4. May 2013

“A framework for fibromyalgia management for primary care providers.” Arnold LM, Clauw DJ, Dunegan LJ, Turk DC; FibroCollaborative Collaborators. Arnold LM, Clauw DJ, Dunegan LJ, Turk DC, Barrow K, Bateman L, Culpepper L, Curtis C, D'Arcy Y, Gebke KB, Gerwin R, Goldenberg DL, Hudson JI, Jain R, Katz AL, Kowal AG, Lapp C, McNett M, Mease PJ, Petersel D, Russell IJ, Stahl SM, Staud R, Wells AF. *Mayo Clin Proc*. 2012 May;87(5):488-96. doi: 10.1016/j. May.2012.

“Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).” Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B; Trial 144 Study Investigators. Rakesh Jain – a Collaborator. *J Clin Psychiatry*. 2011 Nov;72(11):1452-64. doi: 10.4088/JCP.11m06878.

“Beyond the resistance: how novel neurobiological understandings of depression may lead to advanced treatment strategies.” Rakesh Jain, WC Jackson. *J Clinical Psychiatry* 2012. Nov;73(11):e30

“A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.” Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. *Int J Neuropsychopharmacol*. 2012 Sep 11:1-9.

“Painful diabetic neuropathy is more than pain alone: examining the role of anxiety and depression as mediators and complicators.” Jain R, Jain S, Raison CL, Maletic V. Curr Diab Rep. 2011 Aug;11(4):275-84. doi: 10.1007/s11892-011-0202-2.

“Improving the recognition and diagnosis of fibromyalgia”. Arnold LM, Clauw DJ, McCarberg BH; FibroCollaborative. Collaborators- Barrow K, Bateman L, Culpepper L, Curtis C, D'Arcy Y, Dunegan L, Gebke KB, Gerwin R, Goldenberg DL, Hudson JI, Jain R, Katz AL, Kowal AG, Lapp C, Mease PJ, Petersel D, Russell IJ, Stahl SM, Turk DC, Wells AF. Mayo Clin Proc. 2011 May;86(5):457-64. doi: 10.4065/mcp.2010.0738.

“Depression and Suicidality in Children and Adolescents” Shailesh Jain, MD, Rakesh Jain, MD. Current Psychiatry. Vol 11, No 5. 21-32. 2012

“Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis” Rakesh Jain; Babcock, Thomas; Teodor Burtea; Dirks, Bryan; Adeyi, Ben; Scheckner, Brian; Lasser, Robert. Child and Adolescent Psychiatry and Mental Health, 5:35. 2011

“Bed Sharing in School-Age Children—Clinical and Social Implications” Shailesh Jain, MD, MPH, ABDA, Rebecca Romack, BS, and Rakesh Jain, MD, MPH. Journal of Child and Adolescent Psychiatric Nursing. 2011

“Substance abuse risk and stimulants for ADHD: A complex relationship”. Shailesh Jain, MD, Rakesh Jain, MD. Current Psychiatry, Vol. 10, No. 8 September 2011

“Clonidine Modified Release as Add-on Therapy to Psychostimulant Medication in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder”. Scott H Kollins, PhD, Rakesh Jain, MD, Matthew Brams, MD, Scott Segal, MD, Robert L Findling, MD, Sharon B Wigal, PhD, Moise Khayrallah, PhD. Manuscript accepted. Pediatrics. The Journal for the American Academy of Pediatrics, 2011

“Clonidine Extended-Release Tablets in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder”. Rakesh Jain, MD, Scott Segal, MD, Scott Kollins, Ph.D., Matt Brams, MD, Moise Khayrallah, Ph.D. Journal of the American Academy of Child and Adolescent Psychiatry, Feb;50(2):171-9. 2011

“Major Depressive Disorder in Primary Care – Best Practices for Achieving and Maintaining Remission”. Rakesh Jain, MD, MPH. PsychClinician Report. April 2011

“Anti-depressants in the Treatment of Chronic Pain”. Rakesh Jain, MD, MPH, Shailesh Jain, MD, MPH. Practical Pain Management. pages 44-50. March 2011

“Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.” Turgay A, Ginsberg L, Sarkis E, Jain R, Adeyi B, Gao J, Dirks B, Babcock T, Scheckner B, Richards C, Lasser R, Findling RL. J Child Adolesc Psychopharmacol. Dec;20(6):503-11. 2010

“Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate.” Katic A, Ginsberg L, Jain R, Adeyi B, Dirks B, Babcock T, Scheckner B, Richards C, Lasser R, Turgay A, Findling RL. *J Atten Disord*. 2010

“Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: Results of the BRITE-MD study”. Leuchter AF, Cook IA, Marangell LB, Gilmer WS, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, McCracken JT, Fava M, Iosifescu D, Greenwald S. *Psychiatry Research*. 2009 Sep 30;169(2):124-31.

“Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.” Leuchter AF, Cook IA, Gilmer WS, Marangell LB, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Fava M, Iosifescu D, Greenwald S. *Psychiatry Research*. 2009. Sept 30;169(2):132-8

“From Chaos to Consilience – Part III Using the new Mind-Body Science to improve the Diagnosis and Treatment of Major Depression.” Charles Raison, MD, Rakesh Jain, MD, MPH, Vladimir Maletic, MD, Jon Druad, MD, MS. *Psychiatric Times*, August 2009

“From Chaos to Consilience – Part II Using the new Mind-Body Science to improve the Diagnosis and Treatment of Major Depression.” Charles Raison, MD, Rakesh Jain, MD, MPH, Vladimir Maletic, MD, Jon Druad, MD, MS. *Psychiatric Times*, June 2009

“From Chaos to Consilience Part I– Using the new Mind-Body Science to improve the Diagnosis and Treatment of Major Depression”. Charles Raison, MD, Rakesh Jain, MD, MPH, Vladimir Maletic, MD, Jon Druad, MD, MS. *Psychiatric Times*, May 2009

“Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.” Findling RL, Ginsberg LD, Jain R, Gao J. *J Child Adolesc Psychopharmacol*. Dec;19(6):649-62. 2009.

“Treating patients with emotional and physical symptoms”. Rakesh Jain, MD, MPH. *J Clin Psychiatry*. May 2009. 70(5):e15

“The Epidemiology and Recognition of Pain and Physical Symptoms in Depression”. Rakesh Jain, MD, MPH. *J Clin Psychiatry*. March 2009. 70(3):e04

“Pain and the Brain: Lower Back Pain”. Rakesh Jain, MD, MPH. *J Clin Psychiatry*. February 2009. 70(2):e41

“Depression as a Mind-Body Disorder in Minority Populations: Special Challenges in Diagnosis and Treatment.” Rakesh Jain, MD, MPH (Moderator), Rahn K. Bailey, MD, Vladimir Maletic, MD, Madhukar H. Trivedi, MD. *Neuropsychiatry Reviews*. November 2008: 16-21.

“Pain and the Brain: Diabetic Neuropathic Pain.” Rakesh Jain, MD, MPH. *Journal of Clinical Psychiatry*. 2008 Aug;69(8):e22

“Clinical Implications of the Overlapping Neurobiology of Pain and Depression.” Michael Clark, MD, MPH, MBA, Jon W. Draud, MD, MS, Rakesh Jain, MD, MPH, Vladimir Maletic, MD. Special Report based on a symposium presented at the American Conference on Pain Medicine held on April 15, 2008 in New York, NY. CME Zone, October 2008

“Alleviating the Burden of Fibromyalgia: A Psychiatrist’s Approach.” Rakesh Jain, MD, MPH. Reporter, a supplement to Psychiatric Times, September, 2008

“Managing Bipolar Disorder from Urgent Situations to Maintenance Therapy.” Rakesh Jain, MD, MPH. Journal of Clinical Psychiatry. 2008 Mar; 69(3):e7

“Alleviating the Burden of Fibromyalgia: A Psychiatrist’s Approach.” Don L. Goldenberg, MD, Rakesh Jain, MD, MPH, Shailesh Jain, MD, MPH. Reporter, a supplement to Psychiatric Times, February, 2008

“A Randomized, Double-Blind Comparison of Duloxetine and Venlafaxine in the Treatment of Patients with Major Depressive Disorder.” David G.S. Perahia, Yili Lu Pritchett, Daniel K. Kajdasz, Michael Bauer, Rakesh Jain, James M. Russell, Daniel J. Walker, Kimberly A. Spencer, Debbie M. Froud, Joel Raskin, Michael E. Thase. Journal of Psychiatric Research, 2008 Jan;42(1):22-34. Epub 2007 Apr 18

“ADHD as a Diagnostic Chameleon”. Saundra Jain, PsyD, Rakesh Jain, MD, MPH. Dialogues in ADHD, vol 4, no 1, 2008

“Managing Bipolar Disorder from Urgent Situations to Maintenance Therapy”. Teleconference based publication. Chair – Rakesh Jain, MD, MPH., J Sloan Manning, Steve Garlow, Vladimir Maletic, W Clay Jackson, Tracy Skale, Noel Gardner. Primary Care Companion of Journal of Clinical Psychiatry, October 2007

“Practical Strategies for Assessing and Stabilizing Bipolar Patients in Urgent Situations.” Skale TG, Jain R. Journal of Clinical Psychiatry, 2007 Oct;68(10):e23

“Importance of a Correct Initial Diagnosis and Stabilization to Avoid Social and Economic Consequences.” Manning JS, Jain R. Journal of Clinical Psychiatry, 2007 Sep;68(9):e22

"Managing Bipolar Disorder from Urgent Situations to Maintenance Therapy, Part 2: Focus on Maintenance” Academic Highlights Chair – Rakesh Jain. Faculty – Vladimir Maletic, W Clay Jackson, Noel Gardner. Journal of Clinical Psychiatry, August 2007

"Managing Bipolar Disorder from Urgent Situations to Maintenance Therapy, Part 1 : Focus on Urgent Situations” Academic Highlights Chair – Rakesh Jain. Faculty – Steve Garlow, Tracy Skale, J Sloan Manning. Journal of Clinical Psychiatry, August 2007

“Effects of Atomoxetine on Growth In Children with ADHD Following Up to Five Years of Treatment” Spencer TJ, Kratochvil C, Sangal RB, Saylor K, Bailey C, Dunn DW, Geller D, Casat

C, Lipetz R, Jain R, Newcorn J, Ruff D, Feldman P, Furr A, Allen AJ. J Child Adolesc Psychopharmacol 2007 Nov;17(5):689-700

“To Split or not to Split?” Clinical Pearls. Rakesh Jain, MD, MPH, Shailesh Jain, MD, MPH. Current Psychiatry. December 2006

“Pros and Cons of Pill Splitting.” Rakesh Jain, MD, MPH, Shailesh Jain, MD, MPH. Journal of Family Practice, vol 5, no 12, December 2006

“Clinical Consult in Depression”, Invited Expert, Rakesh Jain, MD, MPH. Published on the Official Website of CME, Inc. <http://www.mhsource.com/depconsult/archive.html>, appearing November 2004

“Out of the Pipeline: Duloxetine: Dual Action Anti-Depressant”. Rakesh Jain, MD, MPH, Shailesh Jain, MD, MPH. Current Psychiatry, appearing November 2004

Book Review. “Bipolar Disorders: A clinician’s Guide to Biological Treatments”. Rakesh Jain, MD, MPH, Shailesh Jain, MD, MPH. Journal of Canadian Psychiatry, appearing in November 2004

“Clinical Consult in Depression”, Invited Expert, Rakesh Jain, MD, MPH. Published on the Official Website of CME, Inc. <http://www.mhsource.com/depconsult/archive.html>, April 2004

“Using the Mind-Body Connection to Improve Detection and Treatment”. Kevin Ferentz, MD. Rakesh Jain, MD, MPH, Charles B. Nemeroff, MD, Ph.D.. CNS News, vol 6, No 5, May 2004, pages 47-52

“Single-Action versus Dual-Action Antidepressants”, Rakesh Jain, MD. The Primary Care Companion, Journal of Clinical Psychiatry. 2004;6(supp 1):7-11

“New Treatments for Depression Characterized by Physical Symptoms”, J Sloan Manning, MD, Rakesh Jain, MD, MPH, Marie Savard, MD, Madhukar Trivedi, MD. JCP Visuals, Journal of Clinical Psychiatry, November 2003

“Functional Outcomes in Children and Adolescents with Attention-Deficit/ Hyperactivity Disorder”, Chair, Rakesh Jain, MD, MPH ; Participants - David Duesenberg, MD, and Craig Donnelly, MD. JCP Visuals, Journal of Clinical Psychiatry July 2003

“Therapeutic Focus-Review and Expert Commentary: ADHD-Pharmacotherapy Challenges and Practical Solutions for the Treatment of Children and Adolescents-A Roundtable Discussion”, featuring Expert Commentary by Craig Donnelly, MD, David Duesenberg, MD and Rakesh Jain, MD, MPH. Jointly sponsored by University of New Mexico School of Medicine and Rogers Medical Intelligence Solutions, 2003.

“Addressing Both the Emotional and Physical Symptoms in Depression”. Rakesh Jain MD, MPH; Nancy Russ – Medical Writer. E-article posted on www.Medscape.com, release date March 21, 2003

“Serotonin and Norepinephrine: Are Two Better Than One?”. Rakesh Jain, MD, MPH, Shailesh Jain, MD, MPH, Psychiatric Times, Vol XIX, No 6, June 2002

“Neuropsychiatric Aspects of Alcohol Abuse in the Elderly”. Rakesh Jain, M.D., M.P.H., John McGuinness, Ph.D., M.D. Geriatric Medicine Today, Vol. 9, No Pages 60-67, 1990

“Descriptive Study of the Mortimer-Filkins Alcoholism Screening Test and Its Use in a Metropolitan Council of Alcoholism”. Master’s Thesis, Rakesh Jain, MD; University of Texas School of Public Health, Houston, Texas, 1987

DOCTORAL THESIS SUPERVISOR:

‘Psychedelic Virtual Reality: A Mixed Methods Study of Psychological Transformation’ – PhD candidate – Sandeep Prakash. California Institute for Integral Studies, 2022. External PhD Advisor.

‘Ketamine Assisted Psychotherapy in a Low-income Culturally Diverse Sample: A Phenomenological Study.’ Dave Rojas, Ph.D. Candidate in Clinical Psychology, California School of Professional Psychology, Alliant International University. External PhD Advisor.

NEWSPAPER EDITORIAL:

‘How to Turn Pandemic PTSD into Post-Traumatic Growth’- Now, our biggest threat is not COVID-19 , but the despair and trauma that come from it. Dallas Morning News, Opinion piece, September 2021.

POSTER PRESENTATIONS:

“The Broad Efficacy of Cariprazine Across Symptoms in Patients With Bipolar I Disorder: Post Hoc Analysis of Randomized, Placebo-Controlled Trials”. Rakesh Jain, Lakshmi N. Yatham, Eduard Vieta, Roger S. McIntyre, Willie R. Earley, Mehul Patel. Poster presented at Presented at the Medscape GME Virtual Poster Hall 2020

“The Rapid Mood Screener: A Novel and Pragmatic Screener Tool for Bipolar I Disorder.” Roger S. McIntyre, Prakash S. Masand, Mehul Patel, Amanda Harrington, Patrick Gillard, Susan L. McElroy, Kate Sullivan, Brendan Montano, T. Michelle Brown, Lauren Nelson, Rakesh Jain Poster presented at The International Society for Bipolar Disorders Annual Conference - 2020 Virtual Meeting, July 2020.

“Impact of Lemborexant Treatment Across 12 Months on Fatigue Severity and Sleep Outcomes in Subjects From SUNRISE-2 With Clinically Significant Fatigue at Baseline”. Rakesh Jain, et al. Poster presented at the Annual Congress of the American Society of Clinical Psychopharmacology (ASCP) Virtual Meeting June 2020.

“Impact of Lemborexant Treatment on Patient-Reported Distress With Sleep and Interference With Daily Functioning Over 6 Months.” Craig Chepke, Rakesh Jain, et al. Poster presented at the Annual Congress of the American Society of Clinical Psychopharmacology (ASCP) Virtual Meeting June 2020

“Metabolic Profile of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder With and Without Attention Deficit Hyperactivity Disorder and Stimulant Use”. Rakesh Jain, Ronald Landbloom, Mary Mckie, Linda Snow-Adam, Robert Findling. Presented at the Annual meeting of the Academy of Child and Adolescent Psychiatry, San Antonio, Texas, USA. October 2015.

“Early Improvement and Sustained Response With Vilazodone in Patients With Major Depressive Disorder: Pooled Analyses From Two Phase III Trials”. Rakesh Jain, MD et.al Presented at the NCDEU Meeting, Boca Raton, Florida. June 2013.

“Early Improvement and Sustained Response With Vilazodone in Patients With Major Depressive Disorder: Pooled Analyses From Two Phase III Trials”. Rakesh Jain, MD et.al Presented at the American Psychiatric Association Annual Meeting, San Francisco, May 2013. Abstract Number: 4029

“L-methyfolate 15 mg as adjunctive therapy with SSRI following acute remission for MDD: results of a 12 month, open label, relapse-prevention study.” ” Rakesh Jain, MD, George Papakostas, Richard Shelton, Maruizio Fava. Presented at the College of Psychiatric and Neurologic Pharmacists Annual Meeting, Tampa, Florida. May 2012

“Personalized Therapy of adjunctive L-methyfolate to SSRI Resistant major depressive disorder” Rakesh Jain, MD, George Papakostas, Richard Shelton, Maruizio Fava. Presented at the College of Psychiatric and Neurologic Pharmacists Annual Meeting, Tampa, Florida. May 2012

“Treatment of ADHD with extended release clonidine – a fixed dose, placebo controlled study in children from the age of 6 to 17”. Rakesh Jain, MD, MPH, Rafael Muniz, MD. US Psychiatric Congress 24th Annual Meeting, Las Vegas, Nevada. 2011

“Treatment Outcomes With Lisdexamfetamine Dimesylate in Children Who Have Attention-Deficit/Hyperact Disorder and Clinically Significant Deficits in Emotional Control”. Alan Katic, MD, Rakesh Jain, et al. American Academy of Child and Adolescent Psychiatry, Annual Meeting, 2011

“Efficacy and Tolerability of Lu AA21004 5 mg in a 6-Week Treatment of Adults With Major Depressive Disorder”. Jain, R., MD, MPH, Mahableshwarkar, A.R., MD, Jacobsen, P., MS, Chen, Y., PhD, Thase, M.E., MD. Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii. 2011

“Clonidine Hydrochloride Extended-Release Tablets for Treatment of ADHD in Pediatric Patients: A Responder Analysis.” Mija Yoon, PharmD; Chao Wang, PhD; Rakesh Jain, MD, MPH; Scott H. Kollins, PhD. Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii 2011

Long-term Safety and Efficacy of Clonidine Extended-Release Tablet Monotherapy or Combination Therapy in Pediatric Patients With ADHD. Samantha Bostrom, MD, Mija Yoon, PharmD. Chao Wang, PhD. Rakesh Jain, MD, MPH. Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii 2011

“Lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder after suboptimal”. Rakesh Jain, Don Duncan, Thomas Babcock, Teodor Burtea, Bryan Dirks, Ben Adeyi, Monica Shaw. Presented at the 14th International Congress of ESCAP – European Society for Child and Adolescent Psychiatry, Helsinki, Finland. June 2011

“Cardiac Safety of Clonidine Modified Release Therapy in Children and Adolescents with ADHD”. Rakesh Jain, MD, Scott Segal, MD, Scott Kollins, Ph.D., Matt Brams, MD, Moise Khayarrh, Ph.D. Poster will be presented at the American Academy of Child and Adolescent Psychiatry’s Annual Meeting, Washington DC, 2010

“Efficacy of Lisdexamfetamine Dimesylate in Children With Attention-Deficit/ Hyperactivity Disorder Recently Treated With Mixed Amphetamine Salts”. Rakesh Jain, MD, Thomas Babcock, DO, Teodor Burtea, MD, Bryan Dirks, MD; Ben Adeyi, MS2, Brian Scheckner, Pharm, Stacey Curtiss, PharmD; Robert Lasser, MD. Presented at the 23rd Annual US Psychiatric and Mental Health Congress; November 18-21, 2010; Orlando, FL.

“Efficacy and Safety of Lisdexamfetamine Dimesylate in Children With Attention-Deficit/Hyperactivity Disorder and Recent Use of Methylphenidate”. Rakesh Jain, MD, Thomas Babcock, DO, Teodor Burtea, MD, Bryan Dirks, MD, Ben Adeyi, MS, Brian Scheckner, PharmD, Robert Lasser, MD, John Renna, PharmD, Don Duncan, MD Presented at the 163rd Annual meeting of the American Psychiatric Association, New Orleans, 2010

“Response and Symptomatic Remission with Open-label Co-administration of Guanfacine Extended Release and Stimulants for ADHD”. Larry Ginsburg, MD, Rakesh Jain, MD, William Murphy, MD, Andrew Lyn, M.Sc., Jonathan Rubin, MD, Sharon Youcha, MD. Presented at the 163rd Annual meeting of the American Psychiatric Association, New Orleans, 2010

“Improvement in Emotional Expression in Children with ADHD Treated with 20 mg to 70 mg of Lisdexamphetamine”. Alan Katic, MD, Lawrence Ginsberg, MD, Rakesh Jain, MD, Cynthia Richards, MD, Robert Findling, MD. Presented at the 162nd Annual meeting of American Psychiatric Association, San Francisco, California, May, 2009

“Improvement in Executive Function in Children with ADHD Treated with 20 mg to 70 mg of Lisdexamphetamine”. Atilla Turgay, MD, Lawrence Ginsberg, MD, Rakesh Jain, MD, Joseph Gao, Ph.D., Cynthia Richards, MD, Robert Findling, MD. Presented at the 162nd Annual meeting of American Psychiatric Association, San Francisco, California, May, 2009 (accepted poster - to be presented in May 2009)

“Developing a Sustained Release Formulation of Clonidine for the Treatment Of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD).” Rakesh Jain, MD, MPH, Scott Kollins, PhD, Charles Bailey, MD, Willis Holloway, MD, H. Joseph Horacek, MD, and

Moise Khayrallah, PhD. Presented at the ACNP 47th Annual Meeting, December 8, 2008, Scottsdale, Arizona.

“A Dose-Optimization Study of the Efficacy and Tolerability of Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder.” Lawrence Ginsberg, MD, Rakesh Jain, MD, Joseph Gao, PhD, Cynthia Richards, MD, Robert Findling, MD. Presented at the 20th Annual Children and Adults with Attention Deficit/Hyperactivity Disorder International Conference; November 12-15, 2008; Anaheim, CA.

“A Dose-Optimization Study of the Efficacy, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder.” Lawrence Ginsberg, MD; Rakesh Jain, MD; Joseph Gao, PhD; Cynthia Richards, MD; Robert Findling, MD. Presented at the 21st Annual U.S. Psychiatric and Mental Health Congress; October 30-November 2, 2008; San Diego, CA.

“A Dose-Optimization Study of the Efficacy, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder.” Robert Findling, MD; Rakesh Jain, MD; Joseph Gao, PhD; Cynthia Richards, MD; Lawrence Ginsberg, MD. Presented at the American Academy of Child & Adolescent Psychiatry Annual Meeting; October 28-November 2, 2008; Chicago, IL.

“Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD): Predictors of Clinical Treatment Response.” Andrew Leuchter, MD, Ian Cook, MD, Lauren Marengell, MD, William Gilmer, MD, Karl Burgoyne, MD, Robert Howland, MD, Madhukar Trivedi, MD, Sidney Zisook, MD, Rakesh Jain, MD, MPH, Daniel Iosifescu, Maurizio Fava, MD, Paul Manberg. Presented at the Society of Biological Psychiatry Meeting, San Diego, May, 2007

“The Problems with ‘Super-Sizing’ in American High Schools: A Survey” Nicholas Moore, Rakesh Jain, MD, MPH, Saundra Jain, PsyD. Poster presented at the Annual meeting of the Society for Nutritional Education, San Francisco, California, July, 2006

“Evaluation of Patient Perceptions of Medication Noncompliance and Identification of Possible Solutions for Improving Compliance with Psychopharmacology.” Rakesh Jain, M.D., M.P.H., Saundra Jain, Psy.D. Presented at the Annual U.S. Psychiatric Congress, San Diego, California, November 2004

“A Survey Assessment of High School Students’ Knowledge and Beliefs Regarding Mental Health Issues.” Nick Moore, Rakesh Jain, M.D., M.P.H., Saundra Jain, Psy.D. Presented at the Annual U.S. Psychiatric Congress, San Diego, California, November 2004

“Parental Assessment of Personality Changes While on Stimulants and then on Atomoxetine.” Rakesh Jain, MD, MPH, Saundra Jain, PsyD. Presented at the New Research Poster Session, Annual meeting of the American Psychiatric Association, New York City, May, 2004

“Use of MMPI as a Therapeutic Tool.” Irvin A. Kraft, M.D., Rakesh Jain, M.D., Avi Raphaeli, Ph.D. Presented at the 10th International Conference on Personality Assessment, held in Brussels, Belgium, July 1987

“MMPI and the Pragmatic Use of Psychopharmacology.” Irvin A. Kraft, M.D., Rakesh Jain, M.D., Avi Raphaeli, Ph.D. Presented at the 10th International Conference on Personality Assessment, held in Brussels, Belgium, July 1987

JOURNAL REVIEWER:

Reviewer – Journal - Journal of Addiction Medicine & Therapy

Reviewer – Journal – Journal of Psychopharmacology

Reviewer – Journal - Nutrients

Reviewer – Journal - Current Drug Abuse Reviews

Reviewer - Journal - Drugs

Reviewer – Journal - Current Psychiatry Reviews

Reviewer – Journal - Therapeutic Advances in Psychopharmacology

Reviewer – Journal - Schizophrenia Research

Reviewer – Journal - International Journal of Clinical Practice

Reviewer – Journal - Journal of Attentional Disorder

Reviewer – Journal - Current Psychiatry

Reviewer – for the University of Alberta Press

Reviewer – Journal - International Clinical Psychopharmacology

Reviewer – Journal - Drugs of Today

Reviewer – Journal - Journal of Clinical Psychiatry

DEPARTMENTAL GRAND ROUNDS PRESENTER:

“Examining the Impact of TD in Clinical Practice”. TD Grand Rounds - Eastern Virginia Medical School, Norfolk, VA, 2021

“Exploring Emerging Therapies in Major Depression”. Department of Psychiatry, University of Florida School of Medicine, Gainesville, Florida. Grand Rounds. December, 2017

“Neurobiology of Depression and Targeting Symptoms to Remission”. Department of Psychiatry, Antiochia Medical School, Medellin, Columbia, South America. Grand Rounds. August 2015.

“Better is Not Well: Neurobiologically based targeting of executive function in ADHD”. Department of Psychiatry, University of Alberta, Canada, Grand Rounds. November 2013.

“Wellness in Psychiatry – Snake Oil, or 21st Century’s New Gold Standard?: Department of Psychiatry, University of Arizona College of Medicine, Tucson, Arizona, December 2012

“Recent Developments in Depression Care. Department of Psychiatry, King Fadh Hospital, Dammam, Saudi Arabia. November 2012

“Measurement Based Care in Psychiatry – Examining the Role of Screeners and Rating Instruments” – Department of Psychiatry and Behavioral Sciences Grand Rounds, University of Texas Medical School – Houston, Texas. November 2011

“Diagnosis and Management of Fibromyalgia – an update for Psychiatrists”. Department of Psychiatry and Behavioral Medicine Grand Rounds, University of Texas Medical School – Houston, Texas. 2010

“Management of Agitation and Aggression in the Medically Il, In-patient Population”, February 2004, Internal Medicine Grand Rounds, Brazosport Memorial Hospital, Lake Jackson, Texas

“ADHD- improved Recognition and Treatment”- February, 2004, Grand Rounds, Devereaux Hospital, presented to physicians and staff, League City, Texas

“Sexuality, Weight Concerns and Depression”, June 2001, Grand Rounds, presentation to physicians and staff at Devereaux Center, League City, Texas

“Recognition and Treatment of Mixed Depression Anxiety States in Medically Ill Patients”, May 1999, Grand Rounds, Presentation Department of Internal Medicine St. Joseph’s Hospital, Houston, Texas

“Recognition and Treatment of Depression Across A Woman’s Life Span”, March 1999, Grand Rounds Presentation Department of Obstetrics and Gynecology, Texas Woman’s Hospital, Houston, Texas

“Recognition and Treatment of Depression Across A Woman’s Life Span”, March 1999, Grand Rounds Presentation, Department of Obstetrics and Gynecology Baylor College of Medicine, Houston, Texas

“Recognition and Treatment of Depression Across A Woman’s Life Span”, March 1999, Grand Rounds Presentation, Department of Obstetrics and Gynecology University of Texas Medical School, Houston, Texas

BOARD CERTIFICATION:

Certified by the American Board of Psychiatry and Neurology, 1993 (lifelong validation of certification).

INVITED APPOINTMENTS:

Invited Member of Steering Committee. US Psychiatric Congress, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023

Invited Member and External Expert and Advisor, Project ‘Blue’ of Lilly Pharmaceuticals. 2012

Invited Member of the CME Slide Development Committee, Discovery CME Educational Channel. Programs on Chronic Pain, Fibromyalgia, and Major Depression. 2010

Invited Member of the CME Slide Development Committee, CME LLC, Mind-Body Program Series. 2009, 2010.

Member of the Board of Directors, CME Institute of Physicians Postgraduate Press, Inc. Memphis, Tennessee. 2006, 2007, 2008, 2009, 2010

Invited Medical and Scientific Reviewer - Psychiatric Times. Irvine, California

Invited CME Content Developer, AdvanceStar Communications. To create the Psychiatry Course Syllabus and slides on Depression, 2005

Invited CME Content Developer, AdvanceStar Communications. To create the Primary Care Course Syllabus on Depression, 2005

Invited CME Content Developer, AdvanceStar Communications. To create the Psychiatry Course Syllabus and slides on Depression, 2004

Invited CME Content Developer, AdvanceStar Communications. To create the Primary Care Course Syllabus on Depression, 2004

CME CONTENT DEVELOPMENT:

US Psychiatric Congress Annual Meetings - Depression, Wellness, ADHD Track – Developer of both Didactic and Case Presentations. 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024

PriMed Fibromyalgia Track – Developer of both Didactic and Case Presentation, 2008, 2009, 2010, 2011

PrimeMed Depression (Primary Care) Track – Developer of the Case Presentation Content 2007, 2009, 2010

PrimeMed Depression (Psychiatry) Track - Developer of Content – 2003, 2005, 2006

PrimeMed Depression (Primary Care) Track – Sole Developer of Content – 2003, 2004, 2005, 2006, 2007

Texas Academy of Family Practice – Sole developer of content for depression – 2004, 2005, 2006

ADVISORY BOARD MEMBERSHIP

Consultant and Advisory Board Member – Axsome Therapeutics – 2022, 2023, 2024

Consultant and Advisory Board Member – AbbVie Pharmaceuticals – 2020, 2021, 2022, 2023, 2024

Consultant and Advisory Board Member – IntraCellular Therapeutics – 2021, 2022, 2023, 2024

Consultant and Advisory Board Member – Biogen and Sage – 2021, 2022, 2023

Consultant and Advisory Board Member – Supernus Pharmaceuticals, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024

Consultant and Advisory Board Member – Tris Pharmaceuticals, 2016

Consultant and Advisory Board Member – Neos Pharmaceuticals, 2016

Consultant and Advisory Board Member – Teva Pharmaceuticals, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024

Consultant and Advisory Board Member, Neurocrine Biosciences, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024

Consultant and Advisory Board Member – Janssen Pharmaceuticals, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024

Consultant and Advisory Board Member – Genentech Pharmaceutical Company, 2012, 2013

Advisory Board Member – Jansen Pharmaceuticals. Focus on Schizophrenia long term care. 2012

Consultant, Advisory Board and Steering Committee Member – US Psychiatric Congress, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2021, 2022, 2023, 2024

Consultant and Advisory Board Member, Shionogi Pharmaceuticals, 2009, 2010, 2011, 2012

Consultant, Deplin Medical and Utilization Board, PamLabs Pharmaceuticals, 2009, 2010, 2011, 2012, 2013

Consultant, ADHD Expert Consortium Meeting, Shire Pharmaceuticals, 2008, 2009, 2010, 2011

Advisory Board Member, Data Analysis Advisory Board, Takeda Pharmaceuticals North America, 2008, 2012, 2015, 2016

Advisory Board Member, US Commercial Advisory Board, Takeda Pharmaceuticals North America, 2008, 2012

Advisory Board Member, Shire Pharmaceuticals Advisory Board, Shire Pharmaceuticals, 2008, 2009, 2010, 2011, 2012, 2016

Advisory Board Member, Forest Pharmaceuticals Advisory Board, Forest Pharmaceuticals, 2008

Advisory Board Member, Guidepoint Global Advisors, Guidepoint Global, LLC, 2008, 2009, 2010, 2011, 2012, 2013

Advisory Board Member, Annual Group Advisory Board, Health & Wellness Partners, 2008

Advisory Board Member, Slide Creation Committee – Pain/Fibromyalgia, Pfizer Pharmaceuticals, 2008

Advisory Board Member, Scientific Education Slide Creation Committee - Insomnia, Takeda Pharmaceuticals, 2008

Advisory Board Member, Symbyax and Treatment Resistant Depression Board, Eli Lilly and Company, 2007, 2008, 2009

Advisory Board Member, Atomoxetine (Strattera) Advisory Board, Eli Lilly and Company, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012

Advisory Board Member, Duloxetine (Cymbalta) Advisory Board, Eli Lilly and Company, 2001, 2002, 2003, 2004, 2005, 2007, 2008, 2009, 2010, 2011

Advisory Board Member, Edivoxetine Advisory Board, Eli Lilly and Company, 2012, 2013

Member, Steering Committee, Welcome Back Awards Committee, 2006, 2007, 2008

Advisory Board Member, Zyprexa and Symbyax Advisory Board, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010

Advisory Board, Roche Diagnostics Psychiatry Advisory Board, 2006, 2007

Board Member, Pediatric Initiative; National Alliance for the Advancement of ADHD Care (NAAAC), 2002, 2003

Member, Psychiatry Scientific Steering Committee, Depression Debate Series, Eli Lilly and Company, 2003

PROFESSIONAL MEMBERSHIPS:

Member-Texas Medical Association-1994 to present

Member-Brazoria County Medical Society-1994 to present

Member-Southern Brazoria County Mental Health Professional Association 1994 to present

INTERNATIONAL CME ACTIVITY:

“Tardive Dyskinesia – Patient and Clinical Perspectives” – Presentation at SIRS Annual Meeting, Florence, Italy, 2024

“Overwhelming Negative Emotions in Psychiatry” – Presentation at the Annual European Psychiatric Association meeting, Budapest, Hungary, 2024

“Norepinephrine and Its Role in Mental Health” – Presentation at Viatris Emerging Market meeting, Istanbul, Turkey, 2024

“Post Traumatic Stress Disorder – Its Clinical and Research Update.” – CME presentation at the European Collage of Neuropsychopharmacology (ECNP), Barcelona, Spain, 2023

“GABA Modulation and Its Impact on Human Neurobiology and Psychiatry Disorders”. CME presentation at European College of Neuropharmacology (ECNP), Vienna, Austria. 2022

“Resilience and Wellness as Antidotes to Stress”. Presentation to Physicians from Canada. CME credit offered. June 2020

“COVID-19 Pandemic and Clinical Wellness and Resilience”. Presentation to the physicians from 11 countries in the Middle East, Africa and Asia. CME offered by Royal College of Physicians, UK. April 2020

Keynote Invited Speaker – “Mixed Mania – Recognition and Treatment in the 21st Century”. 5th Annual CNS Summit, Dubai, United Arab Emirates. February 2017

Keynote Invited Speaker – “Wellness in Psychiatry and Its Implications for Modern Day Practitioners”. Bahrain Ministry of Health, Manama, Bahrain. February 2017

Invited Presenter – “SNRIs and Their Role in the Treatment of Major Depression”. King Khalid Hospital, Riyadh, Saudi Arabia. February 2017

Invited Presenter – “Addressing Major Depression to Remission and Managing Side-effects”. Health Care Summit. Johannesburg, South Africa. April, 2016

Invited Presenter – “Addressing Major Depression to Remission and Managing Side-effects”. Health Care Summit. Johannesburg, South Africa. April, 2016

Invited Presenter – “Addressing Major Depression to Remission and Managing Side-effects”. Health Care Summit. San Jose, Costa Rica. February, 2016

Invited Presenter – “Chronic Pain and Mental Health Overlap – Practical Tips on Optimum Management”. Health Care Summit. San Jose, Costa Rica. February, 2016

Invited Presenter – “Addressing Major Depression to Remission and Targeting Physical and Emotional Symptoms”. Ministry of Health. Dubai, United Arab Emirates. October 17, 2015

Invited Presenter – “Chronic Pain and its Mental Health Overlap – Clinical Applications”. NeuroPath Finder Conference on Chronic Pain. Dubai, United Arab Emirates. October 16, 2015

Chairman, and Invited Presenter – Latin America 7st Pain and 2nd Neurosciences Summit. Mexico. May 2013

Invited Presenter – “ADHD and Its Co-morbidities” APREBA Annual Psychiatry Conference, San Juan. Puerto Rico. April 27, 2013 -

Invited Presenter – “Remission in Depression: Examining the Neurobiological Impact of Remission on the Brain and the Body”. Matsuyama, Japan. August 2012

Invited Presenter – “Remission in Depression: Examining the Neurobiological Impact of Remission on the Brain and the Body”. Kuala Lumpur, Malaysia. July 2012

Invited Speaker – “Overlapping Neurobiology of Pain and Psychological Factors – Clinical Implications” Milan, Italy. August 2012

Invited Presenter – “Remission in Depression: Examining the Neurobiological Impact of Remission on the Brain and the Body”. Hong Kong, China. June 2012

Invited Presenter – “Neurobiology of Depression – Lessons for the Practicing Clinician”. Saudi Arabia Psychiatry Association sponsored meeting, Jeddah, Saudi Arabia. November 2011

Invited Presenter – “Neurobiology of Depression – Lessons for the Practicing Clinician”. Saudi Arabia Psychiatry Association sponsored meeting, Riyadh, Saudi Arabia. November 2011

Invited Presenter – “Neurobiology of Depression – Lessons for the Practicing Clinician”. Saudi Arabia Psychiatry Association sponsored meeting, Dammam, Saudi Arabia. November 2011

Invited Presenter – “Emerging Information on Major Depression and its Neurobiology – Clinical Implications”. Psychiatric Association of Mexico, Vera Cruz, Mexico. November 2011

Invited Presenter – “Major Depression and its Neurobiology – Lessons for Primary Care and Psychiatry”. 3rd Annual Psychiatry Update. Renaissance Hospital Annual Meeting, Edinburg, Texas November 2011

Invited Presenter – “Emerging Neurobiology of Depression – Lessons for the 21st Century Clinician”. Columbia Depression Summit. San Andres, Columbia, South America. October 2011

Invited Presenter – “Is Pain a Neurodegenerative Disorder – The Clinical Implication of New Findings”. 5th Latin America Pain Forum, Buenos Aires, Argentina. October 2011

Invited to serve as a Collaborating Physician Investigator: The DSM-5 Field Trials. DSM-V Committee. 2011

Invited Presenter – “Depression: Optimized treatment Options in the 21st Century”. Guatemala City, Guatemala. August 2011

Invited Presenter – “Depression: Optimized treatment Options in the 21st Century”. Riyadh and Jeddah, Saudi Arabia. June 2011

Invited Presenter – “Psychology of Pain – Impact on Diabetic Neuropathic Pain” – Pain Society Annual Meeting, Stockholm, Sweden, September 2010

CONTINUING EDUCATIONAL SEMINARS:

“PTSD – Examining the Clinical and Research Data” – Elevate Annual meeting, Las Vegas, Nevada, 2024

“Precision Psychiatry and the Role of Precise Serotonergic Receptor Based Treatments in MDD”– Elevate Annual Meeting, Las Vegas, Nevada, 2024

“From Beethoven to Beyonce”: Music and Its Neurobiology and Clinical Applications in Psychiatry” – CME presentation, Psych Congress Nashville, 2023

“Glorious Glutamate – Examining the Value of This Neurotransmitter in Psychiatry”. American Psychiatric Nurse Practitioner Association Annual Meeting, Chicago, 2023

“Neurobiology of GABA – Research Finding and Clinical Applications” – Psych Congress, New Orleans, 2022

“Major Depression – Recognition and Treatment in the Modern Age”. Medscape CME online presentation, New York, New York, January 2017

“Serotonin Receptor Pharmacology” – US Psych Congress Annual CME Meeting, San Antonio, Texas, October 2016

“Generalized Anxiety Disorder – an Modern Update”. Global Medical Education Annual CME Psychopharmacology Update, Scottsdale, Arizona. 2016

“Prevention of Diversion and Misuse of Stimulant Medications for ADHD”. Medscape CME online. Tim Wilens, Scott Kollins, Rakesh Jain.

<http://www.medscape.org/viewarticle/844481?src=emailthis>. May 2016

“Wellness in Psychiatry – Practical Applications”. Arizona Psychiatric Associations. Annual CME Meeting, Scottsdale, Arizona. April 2015.

“Serotonin Receptors and Mental and Physical Health – Advancing Care by Reducing Risks and Increasing Benefits”. Puerto Rico Academy of Psychiatry Annual CME Meeting, September 2014.

CME Presenter – “Depression – Targeting to Remission” University of California at Davis Annual Update, Napa, California. March 2014.

CME Presenter – “Examining the Role of Receptor Pharmacology in Improving Depression Outcomes”. US Psychiatric Congress Regional Meetings. Chicago, Illinois, September 2012

CME Presenter – “Examining the Role of Receptor Pharmacology in Improving Depression Outcomes”. US Psychiatric Congress Regional Meetings. Boston, MA. June 2012

CME Presenter – “Bipolar Disorder Identification and Treatment Issues” University of California at Davis Annual Update, Napa, California. April 2012

CME Presenter – “Examining, and Exploiting the Psychology of Pain to Optimize Outcomes”. Pain Master Class, Oxford, United Kingdom. September 2011

CME Presenter – ADHD – Modern Developments in ADHD with Focus on Augmentation Therapy”. CME LLC Regional CME Meeting, Newport Beach, California. August 2011.

CME Presenter – “Fibromyalgia – Utilizing Measurement Based Care to Improve Outcomes” – Rakesh Jain, MD. CME Outfitters, web conference, August, 2011

CME Presenter – “Pain and Fibromyalgia – An Update”. Presenter – Rakesh Jain, MD, MPH. Presented at the dinner meeting of Singapore Association of Pain Clinicians. July 2011. Singapore.

CME Presenter – “Psychological and Psychiatric Aspects of Pain Disorders – Focus on Fibromyalgia” – presenter – Rakesh Jain, MD, MPH. Presented at the 7th Annual Indonesia Neurological Association meeting. July 2011. Manado, Indonesia

CME Presenter – “Neurobiology of Depression – An Update for the 21st Century Clinician” – presenter – Rakesh Jain, MD, MPH. Saudi Arabia Psychiatry Society, German Hospital Annual Meeting, June 2011. Jeddah, Saudi Arabia

CME Presenter – “Physical Exercise & Mental Health: Is it time to start Prescribing it?” presenter - Rakesh Jain, MD, MPH. APA Annual Meeting – Alaska Chapter. April 15, 2011. Alyasha Resort, Girdwood, Alaska

“Positive Mental Wellbeing: Practical Applications in a Psychiatric Practice” CME presenter - Rakesh Jain, MD, MPH. APA Annual Meeting – Alaska Chapter. April 16, 2011. Alyasha Resort, Girdwood, Alaska

CME Presenter – “MBCT (Mindfulness Based Cognitive Therapy) – What is it and how it Applies to our Practice” – Rakesh Jain, MD, MPH. APA Annual Meeting – Alaska Chapter. April 16, 2011. Alyasha Resort, Girdwood, Alaska

CME Presenter – Keynote Speaker – 9th Annual University of California at Davis Clinical Pharmacology Conference, April 9, 2011. “A New Perspective on Co-morbidity Between Mood Disorders and General Medical Conditions and Clinical Wisdom Updated: Recent Learnings from Neurobiology of Mood Disorders”. Napa, California.

CME Presenter – Fibromyalgia- Dispelling the Myths and Optimizing Outcomes. May 6, 2010. Anaheim, California

CME Presenter – Depression: Optimizing Outcomes in Primary Care and Psychiatry. April 17, 2010. Phoenix, Arizona

CME Presenter – Depression: Optimizing Outcomes in Primary Care and Psychiatry. April 10, 2010. Dallas, Texas

CME Presenter – Depression: Optimizing Outcomes in Primary Care and Psychiatry. March 27th, 2010. Atlanta, Georgia

CME Presenter – Breaking the Chains of Anxiety and Pain. Symposia Title – changing the Paradigm of Pain. British Pain Society Annual Meeting, March 31, 2009

CME Presenter – Chemical Dependency Track at PriMed Access Program. March 2009. New York City, New York.

CME Presenter – Chemical Dependency Track at PriMed Access Program. March 2009. Indianapolis, Indiana.

CME Presenter – Chemical Dependency Track at PriMed Access Program. March 2009. San Diego, California.

CME Presenter – The Mind-Body Link in Unipolar and Bipolar Disorders: Implications for a New Treatment Paradigm 3.5 CME Credit. The Institute for Continuing Healthcare Education. Cincinnati, Ohio. November 8, 2008.

CME Presenter – Navigating the Clinical Conundrum of Major Depressive Disorder 1.5 CME credits. US Psychiatric and Mental Health Congress, San Diego, California. October 31, 2008.

CME Presenter – A ‘Hands On’ Workshop for Diagnosing Fibromyalgia in Your Busy Practice 1.25 CME credits. US Psychiatric and Mental Health Congress, San Diego, California. October 31, 2008.

CME Co-Presenter – Encore Presentation: A Busy Clinician’s ‘Treasure Chest’: Creating a Tool Box Filled with Screeners and Rating Instruments to Improve Patient Outcomes 1.25 CME credits. US Psychiatric and Mental Health Congress, San Diego, California. October 31, 2008.

CME Co-Presenter – A Busy Clinician’s ‘Treasure Chest’: Creating a Tool Box Filled with Screeners and Rating Instruments to Improve Patient Outcomes 1.25 CME credits. US Psychiatric and Mental Health Congress, San Diego, California. October 30, 2008.

CME Presenter – The Mind-Body Link in Unipolar and Bipolar Disorders: Implications for a New Treatment Paradigm 3.5 CME Credit. The Institute for Continuing Healthcare Education. Chicago, Illinois. September 27, 2008.

CME Presenter – The Mind-Body Link in Unipolar and Bipolar Disorders: Implications for a New Treatment Paradigm 3.5 CME Credit. The Institute for Continuing Healthcare Education. New York, New York. September 13, 2008.

CME Presenter – The Mind-Body Link in Unipolar and Bipolar Disorders: Implications for a New Treatment Paradigm 3.5 CME Credit. The Institute for Continuing Healthcare Education. Houston, Texas. September 6, 2008.

CME Presenter – The Mind-Body Link in Unipolar and Bipolar Disorders: Implications for a New Treatment Paradigm 3.5 CME Credit. The Institute for Continuing Healthcare Education. Portland, Oregon. August 23, 2008.

CME Presenter – The Mind-Body Link in Unipolar and Bipolar Disorders: Implications for a New Treatment Paradigm 3.5 CME Credit. The Institute for Continuing Healthcare Education. Seattle, Washington. August 16, 2008.

CME Presenter – Pediatric Bipolar Disorder: Separating Facts from Fiction 1 hour CME Credit. Bayamon Psychiatric Association. San Juan, Puerto Rico. August 9, 2008

CME Presenter – The Mind-Body Link in Unipolar and Bipolar Disorders: Implications for a New Treatment Paradigm 3.5 CME Credit. The Institute for Continuing Healthcare Education. San Francisco, California. July 19, 2008.

CME Presenter – Understanding the Role of Alpha-2 – Extended release clonidine – in ADHD. AAPA Annual Conference, Las Vegas. June 2011.

CME Presenter – “Depression and Pain - Improving Outcomes for Patients” 1.5 hour CME Credit. Accelmed. Washington, District of Columbia. May 17, 2008

CME Presenter – Fibromyalgia: New Developments for the Clinician 1.25 hour CME Credit. CME LLC Regional Extensions. Atlanta, Georgia. April 26, 2008

CME Presenter – Alleviating the Burden of Chronic Pain: A Physical and Emotional Approach 1 hour CME Credit. Puertorrican College of Neuropsychopharmacology. San Juan, Puerto Rico. April 19, 2008

CME Presenter – Fibromyalgia: New Developments for the Clinician 1.25 hour CME Credit. CME LLC Regional Extensions. Houston, Texas. April 12, 2008

CME Presenter – Fibromyalgia: New Developments for the Clinician 1.25 hour CME Credit. CME LLC Regional Extensions. Los Angeles, California. April 5, 2008

CME Presenter – Fibromyalgia: New Developments for the Clinician 1.25 hour CME Credit. CME LLC Regional Extensions. New York, New York. March 29, 2008

CME Presenter – New Developments in Fibromyalgia. 1.25 hours of CME credit. Primed Meeting, Dallas, Texas. March 26, 2008

CME Presenter – Fibromyalgia: New Developments for the Clinician 1.25 hour CME Credit. CME LLC Regional Extensions. San Francisco, California. March 8, 2008

CME Presenter – Fibromyalgia: New Developments for the Clinician 1.25 hour CME Credit. CME LLC Regional Extensions. Washington, DC. March 1, 2008

CME Presenter - Depression: Alleviating the Symptoms. 1.5 hrs CME Credit. 1.5 hrs CME Credit. AA-PE Indianapolis, Indiana. November 3, 2007

CME Presenter - Bipolar Disorder: Improving Outcomes 1.5 hrs CME Credit. AA-PE Indianapolis, Indiana. November 3, 2007

CME Presenter - Bipolar Disorder: Improving Outcomes 1.5 hrs CME Credit. AA-PE. Phoenix, Arizona. October 27, 2007

CME Presenter – Fibromyalgia: New Developments for the Clinician 1.25 hour CME Credit. CME LLC Regional Extensions. Orlando, Florida. October 13, 2007

CME Presenter – Depression and Physical Symptom Overlap: Optimizing Clinical Outcomes. 1 hour CME Credit. CME LLC Regional Conference. Orlando, Florida. October 12, 2007

CME Presenter – Depression and Its Neurobiology. 1.25 hours of CME credit. Primed Meeting, Houston, Texas. October 4, 2007

CME Presenter – ADHD – Special Topics. 1.5 hours of Credit. Haymarket Medical Inc. Stamford, Connecticut. June 2, 2007

CME Presenter – ADHD – Special Topics. 1.5 hours of Credit. Haymarket Medical Inc. Philadelphia, Pennsylvania. May 19, 2007

CME Presenter – Depression and Physical Symptom Overlap: Optimizing Clinical Outcomes. 1 hour CME Credit. CME LLC Regional Conference. Detroit, Michigan. March 24, 2007

CME Presenter – Depression and Its Neurobiology. 1.25 hours of CME credit. Primed Meeting, Minneapolis-St. Paul. March 23, 2007

CME Presenter – Depression and Its Neurobiology. 1.25 hours of CME credit. Primed Meeting, Denver, Colorado. March 20, 2007

CME Presenter – Depression and Physical Symptom Overlap: Optimizing Clinical Outcomes. 1 hour CME Credit. CME LLC Regional Conference. Los Angeles. California March 17, 2007

CME Presenter – Depression and Physical Symptom Overlap: Optimizing Clinical Outcomes. 1 hour CME Credit. CME LLC Regional Conference. Chicago, Illinois. March 10, 2007

CME Presenter – Depression and Physical Symptom Overlap: Optimizing Clinical Outcomes. 1 hour CME Credit. CME LLC Regional Conference. Philadelphia, Pennsylvania. March 3, 2007

CME Presenter – Depression and Its Neurobiology. 1.25 hours of CME credit. Primed Meeting, Long Beach, California March 2, 2007

CME Presenter – ADHD – Special Topics. 1.5 hours of Credit. Haymarket Medical Inc. St. Louis, Missouri. February 20, 2007

CME Presenter – ADHD and Diversion – New Findings. 3 hours of CME credit. Optima Educational Services. Oakbrook, Chicago. December 9, 2006

CME Presenter – ADHD – Special Topics. 1.5 hours of Credit. Haymarket Medical Inc. Boulder, Colorado. December 5, 2006

CME Presenter – ADHD and Diversion – New Findings. 3 hours of CME credit. Optima Educational Services. Atlanta, Georgia. December 2, 2006

CME Presenter – Depression and Its Neurobiology. 1.25 hours of CME credit. Primed Meeting, Richmond, Virginia, November 30, 2006

CME Presenter – Physical Symptoms and Depression. CME Inc's Annual Meeting. 1.5 hours of CME. New Orleans, Louisiana. November 17, 2006

CME Presenter – Depression and Its Neurobiology. 1.25 hours of CME credit. Primed Meeting, Omaha, Nebraska, October 25, 2006

CME Presenter – ADHD across the Life Span. CME Enterprise. Presented at the American Osteopathic Association Annual Meeting. 2 hours of CME. Las Vegas, Nevada. October 20, 2006

CME Presenter – Bipolar Disorder across the Life Spectrum. 3 Hours of CME. Department Of Psychiatry, University of South Dakota Medical School, Sioux Falls, South Dakota, October 7, 2006

CME Presenter – Bipolar Disorder in Children and Adolescents. 1 hour CME credit, Dr. Harold Brandt's Clinic, Baton Rouge, Louisiana, August 24, 2006

CME Presenter – “Treating the Emotional and Physical Symptoms of Depression”. PrimeMed CME program. Philadelphia, Pennsylvania. December 8 , 2005

CME Presenter – “Treating the Emotional and Physical Symptoms of Depression”. PrimeMed CME program. Miami, Florida. .December 6, 2005

CME Presenter – “Treating the Emotional and Physical Symptoms of Depression”. PrimeMed CME program. Chicago, Illinois. November 30, 2005

CME Presenter – “Treating the Emotional and Physical Symptoms of Depression”. PrimeMed CME program. Westchester, New York. October 27 , 2005

CME Presenter – “Treating the Emotional and Physical Symptoms of Depression”. PrimeMed CME program. Los Angeles, California. September 16, 2005

CME Presenter – “Treating the Emotional and Physical Symptoms of Depression”. PrimeMed CME program.(for Psychiatrists San Francisco, California. September 29, 2004

CME Presenter – “Treatment to Optimization – Successful Goal Setting in Psychiatry”. Audience – Dean Foundation Physicians, Madison, Wisconsin. September 16, 2004

CME Presenter – “Treating the Emotional and Physical Symptoms of Depression”. PrimeMed CME program. San Jose, California. June 19, 2004

CME Presenter – “Treating the Emotional and Physical Symptoms of Depression”. PrimeMed CME program. San Francisco, California. April 29, 2004

CME Presenter – “Treatment of Bipolar Disorder in all It’s Phases”. American College of Physicians, 2 hr CME Program. New Orleans, April 24, 2004

CME Presenter – “Diagnosing and Treating ADHD- a Teleconference”. Sponsored by the University of Minnesota and Ingenix Company, 1 hour CME program April 10, 2003

CME Presenter – “Diagnosing and Treating ADHD- a Teleconference”. Sponsored by the University of Minnesota and Ingenix Company, 1 hour CME program April 8, 2003

CME Presenter, “Diagnosis and Treatment of Major Depression – Achieving Optimum Outcomes”, Sponsored by Texas Academy of Family Physicians, Austin, Texas, April 11, 2003

CME Presenter, “Diagnosis and Treatment of ADHD: Audio-CME presentation, Ingenix Corporation, Sponsored by University of Minnesota, April 10, 2003

CME Presenter, “Diagnosis and Treatment of ADHD: Audio-CME presentation, Ingenix Corporation, Sponsored by University of Minnesota, April 8, 2003

CME Presenter, “Dual Action Agents in the Treatment Of Depression and Somatic Symptoms: Focus on a new Dual Action Medication”, sponsored by Simpatico Resources, American Association of Managed Care Pharmacists, Washington, DC. October 11, 2002

CME Presenter, “Dual Action Agents in the Treatment Of Depression and Somatic Symptoms: Focus on a new Dual Action Medication”, sponsored by Medical Economics, San Jose, California, October 18, 2002

CME Presenter, “Optimizing Treatment of Depression”, sponsored by Texas Academy of Family Physicians, Hyatt Hill Country, San Antonio, Texas, October 5, 2002

CME Presenter, “Dual Action Agents in the Treatment Of Depression and Somatic Symptoms: Focus on a new Dual Action Medication”, sponsored by Medical Economics, Cincinnati, Ohio. October 4, 2002

CME Presenter “Dual Action Agents in the Treatment Of Depression and Somatic Symptoms: Focus on a new Dual Action Medication”, Sponsored by Optima Educational Solutions and University of California at Irvine, Beverly Hills, California, July 26, 2002

CME Presenter “Dual Action Agents in the Treatment Of Depression and Somatic Symptoms: Focus on a new Dual Action Medication”, Sponsored by Optima Educational Solutions and University of California at Irvine, Milwaukee, Wisconsin, July 19, 2002

CME Presenter - Presenter, - “Emotional and Physical Symptoms in Depression”, Credits approved by University of California at Irvine Miami, FL, June 20, 2002

CME Presenter - “Emotional and Physical Symptoms in Depression” , Credits approved by University of California at Irvine, Dallas, June 11, 2002

CME Presenter - – “Emotional and Physical Symptoms in Depression: Focus on Serotonin And Norepinephrine”, sponsored by Medical Economics, Seattle, May 31, 2002

CME Presenter – “Sexual and Weight Issues in The Management of Major Depression”, sponsored by Texas Academy of Family Practice Physicians, Hyatt at Town Lake, Austin, Texas May 18, 2002

CME Presenter – “Emotional and Physical Symptoms in Depression: Focus on Serotonin And Norepinephrine”, sponsored by Medical Economics, Long Beach, California, May 10, 2002

CME Presenter, “Optimizing Treatment of Depression In the Family Practice Setting: Focus-Norepinephrine And Serotonin”, Grand Rounds, Presbyterian Hospital, Dallas, TX, May 7, 2002

CME Presenter – “Optimizing Treatment of Depression In the Family Practice Setting: Focus-Norepinephrine And Serotonin”, PrimeMed CME Program, Houston, Texas, March 14, 2002

CME Presenter –“Norepinephrine & Serotonin: Are Dual Anti-Depressants Superior to Single Mechanism Medications” Intercontinental Barkley Hotel New York, NY, March 7, 2002

CME Presenter-Featured Speaker, CME Inc., “Remaining Unmet needs in Depression, Achieving Remission for the Depressed Patient”, Hartford, CT, December 12, 2001

CME Presenter – Brown Schools of San Antonio Annual CME Conference, “Management of Sexual and Weight Side-Effects in Anti-Depressant Usage”, San Antonio, TX, November 17, 2001

CME Presenter - Featured Speaker, CME Inc., “Remaining Unmet Needs in Depression, Achieving Remission for the Depressed Patient”, Deerborn, MI, November 7, 2001

CME Presenter - Featured Speaker, “Remaining Unmet Needs in Depression, Achieving Remission for the Depressed Patient”, CME Inc., Washington, D.C., November 1, 2001

CME Presenter -Featured Speaker, “Remaining Unmet Needs in Depression, Achieving Remission for the Depressed Patient.” CME Inc., Chicago, IL, October 23, 2001

CME Presenter-Texas Academy of Family Physicians, CME review course, “Improved Management of Sexual and Weight Issues in the Depressed Patient”. Omni Hotel, Houston, Texas. November 11, 2000

CME Presenter-“New Development in the Overlap Between Mood Disorders and Schizophrenia”, III Forks Restaurant, Dallas, Texas. November 8, 2000.

CME Presenter-Texas Academy of Family Physicians, CME Review Course, “Improved Management of Depressed Patients in a Family Practice”. Houstonian Hotel, Houston, Texas. August 5, 2000

CME Featured Speaker-“Improved Management of Bipolar Disorder”, Tavern on the Green Restaurant, Brooklyn, New York City, NY, July 27, 2000. (1 hour CME credit offered)

CME Featured Speaker-CME Staff Meeting, Doctor’s Hospital Groves Texas, “Improved Management of Depression in the Depressed and Anxious Patient”, July 10, 2000

Featured Speaker, Council on Substance Abuse, “Brave New Brain, Coming Soon to a Pharmacy near You”, ME Program Angleton, TX, August 17, 2001

CME - Educational Seminar for employees of Brazoria County Juvenile Detention Center, “Identifying and Working With Juveniles Suffering From Depression”, Brazoria County Juvenile Detention Center, Angleton, TX, June 29, 2001

CME - Educational Seminar for employees of Brazoria County Detention Center, “Identifying and Working with an Anti-social Youth Population”, Angleton, Texas, April 18, 2001

Seminar Leader - Mental Health Professional Association, “Applying the DMSIV to Your Practice”, Brazosport Memorial Hospital Annex, Lake Jackson, TX, March 30, 2001 (3 hours of credit offered)

Seminar Leader - Center for Mental Health, “Anxiety Disorders in Children and Adults”, Chili’s Restaurant, Lake Jackson, Texas March 8, 2001 (2 LPC credit hours offered)

Seminar Leader - COSA Workshop, Angleton, Texas, “Working With the Antisocial Personality and Dealing With Substance Abuse Issues”, February 23, 2001 (3 hours credit offered)

Seminar Leader - Second Annual Workshop Brazosport Memorial Hospital, “Bipolar Disorder-Recent Development in Recognition and Treatment”, May 1999 (6 hours CME offered)

Seminar Leader - First Annual Workshop Brazosport Memorial Hospital, Recent Developments in Psychiatry” May 1998 (6 hours CME offered)

MEDIA PRESENTATIONS:

“ADHD and Anxiety Disorder in Women – Why IS it So Complicated to Tell Them Apart?”- a print interview in LiveStrong.com, 2023

Cognitive Challenges in Clinical Practice” –a video based educational seminar. Recording at 718 Studios, Austin, Texas. July 2015.

Smartphone apps become 'surrogate therapists' – Elizabeth Landau. Interviewed Expert for CNN online article on Apps for Mood Regulation. September 2012

“Role of Measurement Based Care in Psychiatry ” . Moderator for web and telephone based CME program. Guest – Madhukar Trivedi, MD. November 2011

“Role of Measurement Based Care in Psychiatry – Advancing Care for Treatment Refractory Depression” . Moderator for web and telephone based CME program. Guest – Michael Thase, MD. November 2011

“Fibromyalgia: One Year Later - The 2010 ACR fibromyalgia criteria capture the broader clinical picture and help ensure more appropriate diagnosis and management by primary care” by Heather Haley. interviewed and quoted as an expert in this report of ‘The Rheumatologist’. July 2011

“What Parents Need to Know about Recent Developments in ADHD’s Treatment” National Radio Show with Bob Gourley. Aired May, 2011

“Bipolar Disorder in Children – Fact or Myth”. CNN Interview. August 2010. Posted at <http://www.cnn.com/2010/HEALTH/08/30/bipolar.kids/?hpt=Sbin>.

“Recognition and Treatment of Fibromyalgia” – Print Media Interview, La Tribuna Newspaper, Houndaras. August 7, 2009

“Recognition and Treatment of Fibromyalgia” – Print Media Interview, Revista Vida Sana, Costa Rica. August 7, 2009

“Recognition and Treatment of Fibromyalgia” – Print Media Interview, Presna Grafica, El Salvador. August 7, 2009

“Recognition and Treatment of Fibromyalgia” – Media Interview, Radio HRN, El Salvador. August 7, 2009

“Recognition and Treatment of Fibromyalgia” – Print Media Interview, Diario Extra, Costa Rica, August 7, 2009

“Recognition and Treatment of Fibromyalgia” – Print Media Interview, Salud Panama, Panama. August 7, 2009

“Recognition and Treatment of Fibromyalgia” – Print Media Interview, Presna Libre, Costa Rica. August 7, 2009

“Recognition and Treatment of Fibromyalgia” – Print Media Interview, La Prensa, Panama. August 7, 2009

“Recognition and Treatment of Depression in America” Support Partners Program. Satellite Media Tour, New York City. Chamberlain Communications, June 12, 2007.

“ADHD and SUD”, an expert interview with Richard Weisler, MD and Rakesh Jain, MD, MPH. Medscape Psychiatry, posted on the web on November 19, 2006

“Tales of the Tape”, quoted as an expert in this news report in the Wall Street Journal, May 25, 2006

“Beating the Holiday Blues”, Television interview WLTV-NBC. Jacksonville, December 16, 2005

“Beating the Holiday Blues”, Television interview WSAV-NBC Savannah, December 16, 2005

“Beating the Holiday Blues”, Radio interview WLW-AM Cincinnati, December 16, 2005

“Beating the Holiday Blues”, Television interview , WGHP-FOX Greensboro, December 16, 2005

“Beating the Holiday Blues”, Radio interview, USA Radio – National, December 16, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. WGIR-AM / Boston. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. WHMP-AM/Springfield. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. ABC Radio Network/National . October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. WOHI-AM/Youngstown . October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. American Urban Radio Network/National. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. WFSS-FM/Raleigh. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. WSBA-AM/Harrisburg. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. WFIN-AM/Toledo. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. KLGR-AM/Minneapolis. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. WDIS-AM/Boston. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. KLGR-AM/Minneapolis. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. Metro Networks/National. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. WBOB-AM/Cincinnati. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. Metro Networks/Nashville Bureau. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. KFNX-AM/Phoenix. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. WWJC-AM/Minneapolis. October 25, 2005

“Recognition and Treatment of Depression in America”. Radio Interview. KFNX-AM/Phoenix. October 25, 2005

“Anxiety in Selected Mental Health Conditions”. Author and Presenter. Web based Training. Creative Streak Productions, August 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. KYM-AM, Philadelphia. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. WRGA-AM, Atlanta. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. WOHI-AM, Youngstown. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. WTBQ-AM, New York. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. WICH-AM, Hartford. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. WTKF-AM, Greenville. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. WICH-AM, Hartford. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. WGAR-AM, Cleveland. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. WAMV-AM, Roanoke. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. WICO-AM, Maryland. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. National News, John Mayer. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. Voice of America, National News. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. WIOD-AM, Miami. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. WEOL-AM, Cleveland. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. WESX-AM, Boston. March 22, 2005

“Recognizing that Depression Hurts Physically and Emotionally”. Radio Interview. KCMN-AM, Colorado. March 22, 2005

“Differentiating Bipolar Depression from Unipolar Depression” DVD Presentation. Saundra Jain, PsyD, Rakesh Jain, MD, MPH. M2 Communications, New Jersey. 2004

“Psychopharmacology: An Update on Current Treatment options.” 50 CME audio program, CME Inc. Co-presenter with 21 presenters, item # DO03197, CME Inc, Irvine, California, 2004

Brazosport Facts (newspaper). “Not just the blues – is your teen’s behavior changing or unbearable?”. By Anna Lara; quoted extensively as an expert in child and adolescent depression. November 16, 2003

M2 Communications created DVD, featured presenter “ADHD – refining treatment options”, April 2003

Channel 2 / NBC Affiliate Health Beat Television Interview on “ADHD and its Treatment”, April 11, 2003

Psychiatric Times – Quoted in CME article “Addressing Both the Emotional and Physical on symptoms in Depression”. CME Educator, March, 2003

Channel 11 / CBS Affiliate Prime Time News, television interview on ‘New Development in ADHD medication treatment’ – March 3, 2003

Brazosport Facts – Newspaper, Interviewed and quoted in article on New Medication in treatment of ADHD – March 3, 2003

AM Radio Station, Houston – Interviewed live on Radio on “ADHD in Adults”, June 16, 2003

FM Radio Station, National Public Radio- Houston, Interviewed on Radio “ADHD in Adults- Medical Perspectives”, June 18, 2003

FM Radio Station, KIKK – Houston, Country Music Radio “ADD and ADHD in the Adult years of life”, June 19, 2003

CME Inc. Educational CD-ROM presentation – “Optimum Treatment of Depression and the Physical Symptoms associated with it’, 2002

CLINICAL TRIALS:

Principal Investigator – Sunovion Pharmaceuticals – “Relapse Prevention study of XXXXXX with lithium or Depakote, vs lithium or Depakote with placebo, after open label stabilization”

Principal Investigator – NeoSync – “Study of Transcranial Magnetic Stimulation vs Sham Treatment of acute major depressive episode”

Principal Investigator – Shire Pharmaceuticals – “Study of Extended release XXXXXXXXX, in comparison to XXXXXXXXX for the treatment of ADHD in children and adolescents”.

Principal Investigator – Shionogi Pharmaceuticals – “ Long Term Relapse Prevention study of XXXXXXXX in children and adolescents with ADHD.

Principal Investigator – Sunovion Pharmaceuticals “Double Blind study of XXXXXXXXX in combination with Lithium or Valproate in assessing for relapse in Bipolar Disorder”

Principal Investigator – Merck Pharmaceutical, “ Double-blind study of XXXXXXXXXXXXX in the treatment of Bipolar Disorder in Adolescents, with a 6 month open label extension”

Principal Investigator – Pfizer Pharmaceutical, “ Use Extended Release XXXXXXXXXXXXX in the treatment of Fibromyalgia—open label stabilization, followed by randomization of detect durability of effect study”

Principal Investigator – Sunovion Pharmaceutical, “ Use of XXXXXXXXXXXXX in the treatment of Bipolar Disorder in combination with lithium/ valproate- open label stabilization, followed by randomization to assess for relapse prevention study”

Principal Investigator – Shire Pharmaceuticals, “ Use XXXXXXXXXXXXX in combinations with stimulants to assess efficacy and tolerability”

Principal Investigator – Takeda Pharmaceutical, “ Use XXXXXXXXXXXXX in the treatment of depression- short and long term study”

Principal Investigator – AstraZeneca Pharmaceuticals, “ Use XXXXXXXXXXXXX in the treatment of depression partially response to SSRIs”

Principal Investigator – Shire Pharmaceutical, “ Use of two different does of XXXXXXXXX in the treatment of ADHD”

Principal Investigator – Otsuka /BMS Pharmaceuticals, “ Use XXXXXXXXXXXXX as an add-on to stimulants in the treatment of partially responsive ADHD”

Principal Investigator – Eli Lilly and Company, “ Use XXXXXXXXXXXXX in the treatment of ADHD”

Principal Investigator – Eli Lilly and Company “ Use XXXXXXXXXXXXX in the treatment of treatment resistant depression”

Principal Investigator – Forest Pharmaceuticals “Use of XXXXXXXXXXXXX in augmentation treatment of Fibromyalgia”.

Principal Investigator – Pfizer Pharmaceuticals “Use of ss-XXXXXXXXXXXX in the treatment of Fibromyalgia”.

Principal Investigator – Eli Lilly and Company “ Use XXXXXXXXXXXXX in the treatment of pediatric major depression”

Principal Investigator – Pfizer Pharmaceutical “ Use XXXXXXXXXXXXX in the treatment of dementia”

Principal Investigator – Eli Lilly and Company “ Use XXXXXXXXXXXX in the treatment of treatment resistant depression”

Principal Investigator – Addrenex Pharmaceuticals Inc. “ Double blind study of Clonidine as augmentation to stimulants in the treatment of ADHD, age 6-17”

Principal Investigator – Addrenex Pharmaceuticals Inc. “ Open label continuation study of Clonidine in the treatment of ADHD, age 6-17”

Principal Investigator – Addrenex Pharmaceuticals Inc. “ Double blind study of Clonidine in the treatment of ADHD, age 6-17”

Principal Investigator – Shire Pharmaceuticals “ Use XXXXXXXXXXXX in the treatment of ADHD”

Sub-Investigator – Jazz Pharmaceuticals. “ Use of XXXXX in the Treatment of Fibromyalgia”.

Principal Investigator – Bristol Myers and Squib “ Use XXXXXXXXXXXX in the treatment of major depression”

Principal Investigator – Novartis. “Use of XXXXXXXXXXXX in the treatment of major depression.”

Principal Investigator – Eli Lilly and Company. “ Use of XXXXXXXXXXXX for augmentation of divalproax in Mixed Mania.”

Principal Investigator – Pfizer. “Augmentation study of XXXXXXXXXXXX in partial responders in Generalized Anxiety Disorder.”

Principal Investigator – Abbott Laboratories. “Short term, safety and efficacy study of XXXX in Adult ADHD.”

Principal Investigator – Eli Lilly and Company. “Short and Long term study of XXXXXXXXXXXX in Fibromyalgia.”

Principal Investigator – Eli Lilly and Company. “XXXXXXXXXXXX in Short and Long term study of XXXXXXXXXXXX in Generalized Anxiety Disorder.”

Principal Investigator – Eli Lilly and Company. “Short and Long term study of XXXXXXXXXXXX in Generalized Anxiety Disorder.”

Principal Investigator – Eli Lilly and Company. “Short and Long term study of XXXXXXXXXXXX in major depression.”

Principal Investigator - Abbott. “Bipolar Disorder – Mania and Mixed Mania study in Children and Adolescents”

Principal Investigator - Pfizer, Inc. “Bipolar Disorder in Children and Adolescents.”

Principal Investigator – Cephalon Pharmaceuticals “A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXXX at 4, 8, and 12 mg/day in the Treatment of Adults With Generalized Anxiety Disorder”

Principal Investigator - Pfizer, Inc. “A Study To Define The Non-Restorative Sleep Population”

Principal Investigator - Forest Pharmaceuticals “A Double-Blind Placebo-Controlled Trial of the Efficacy and Safety of XXXXX in the Treatment of Bipolar Depression”

Principal Investigator - New River Pharmaceuticals “ A Two-Year, Open-Label, and Single-Arm Study of XXXXX 30mg, 50mg, or 70mg Per Day in Children Aged 6-12 Years with Attention Deficit Hyperactivity Disorder (ADHD)”

Principal Investigator - New River Pharmaceuticals “A Phase 3, Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study of XXXX in Children Ages 6-12 Years with Attention Deficit Hyperactivity Disorder (ADHD)”

Principal Investigator - Corcept Pharmaceuticals “A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Three Dose Levels of XXXXXX Plus An Antidepressant vs. Placebo Plus An Antidepressant in the Acute Treatment of Patients with Major Depressive Disorder with Psychotic Features (PMD)”

Principal Investigator - Shire Pharmaceuticals “A phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-Group, Safety and Efficacy Study of XXXXX and Open-label Extension in Adolescents with Attention-Deficit Hyperactivity Disorder (ADHD)”

Principal Investigator - Shire Pharmaceuticals “A phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-Group, Safety and Efficacy Study of XXXXX with an Open-label Extension in Adults with Attention-Deficit Hyperactivity Disorder (ADHD)”

Principal Investigator - Shire Pharmaceuticals “A phase II, Open-Label Co-Administration Study of XXXXX AND XXXXXXXX in Children and Adolescents Aged 6-17 with Attention-Deficit Hyperactivity Disorder (ADHD)”

Principal Investigator - Shire Pharmaceuticals “A Phase IIIb, Open-Label, Multi-Center Study to Assess Safety, Tolerability, and Effectiveness Associated with the use of XXXXXX in Adults with Attention Deficit Hyperactively Disorder and Evaluate an ADHD-specific Novel Quality of Life Measure”

Principal Investigator - Shire Pharmaceuticals “A Phase III, Open-Label Study of XXXXX in Children and Adolescents Aged 6-17 with Attention Deficit Disorder (ADHD)”

Principal Investigator - Shire Pharmaceuticals “A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of XXXX in Children and Adolescents Aged 6-17 with Attention Deficit Disorder (ADHD)”

Principal Investigator - Pfizer Inc. “A randomized, double-blind, placebo-controlled study of continuation treatment with XXXXXXXX in the treatment of adolescents with primary diagnosis of Panic Disorder”

Principal Investigator - Pfizer Inc. “An open-label study to assess the safety and tolerability of XXXXXXXX in the treatment of adolescents with Panic Disorder or Anxiety with Panic Attacks”

Principal Investigator - Pfizer Inc, “A randomize, double-blind, placebo-controlled study of XXXXXX in the treatment of adolescents with primary diagnosis of Panic Disorder”

Principal Investigator - GlaxoSmithKline “A Multicenter, Double-Blind Placebo-Controlled Comparison of the Efficacy and Safety of Flexible Dose Extended-Release XXXXXXXX 300-450 mg/day and Placebo Administered for Eight Weeks for the Treatment of Adult Outpatients with Major Depressive Disorder and Symptoms of Decreased Energy, Pleasure, and Interest”

Principal Investigator - Forest Research Institute “A Double-Blind Placebo-Controlled Trial of the Efficacy and Safety of XXXXXXXX in the Treatment of Bipolar Depression”

Principal Investigator - Bristol-Myers Squibb “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of XXXXXXXX in the Treatment of Patients with Bipolar I Disorder with a Major Depressive Episode”

Principal Investigator – Eli Lilly and Company “ XXXXXXXXXXXX / XXXXXXXXXXXX Combination vs. Lamotrigine in the Treatment of Bipolar I Depression”

Principal Investigator – Forest Research Institute. “A double-blind dose comparison of XXXXXXXXXXXXXX , venlafaxine - XR and placebo in the treatment of Generalized Anxiety Disorder”

Principal Investigator – Eli Lilly and Company, “Evaluation of continuous symptom treatment of ADHD: a placebo controlled double blind assessment of morning dose or evening dosed XXXXXXXXXXXX,

Principal Investigator –Forest Research Institute. “A double-blind dose comparison of XXXXXXXXXXXXXX , sertraline and placebo in the treatment of Major Depression”

Principal Investigator –Organon, Inc. “ A multi-center, double-blind, placebo-controlled, flexible dose, safety and efficacy study of Org XXXXXX ER in outpatient children and adolescents with major depression”

Principal Investigator –Shire Pharmaceutical Development, Inc. “ A phase III, multi-center, double-blind, parallel group, placebo-controlled safety and efficacy study of XXXXXXXX-XR in adolescents aged 13-17 with ADHD”

Principal Investigator – Shire Pharmaceutical Development, Inc. “ A phase III, open label study of XXXXXXXX in children and adolescents (age 6-17 years)

Principal Investigator –Shire Pharmaceutical Development, Inc. “ A phase III, randomized, multi center, placebo controlled safety and efficacy study of XXXXXXXX in children and adolescents, aged 6-17 with ADHD”

Principal Investigator –Merck Pharmaceuticals, “ A double-blind, multi-center, placebo and active controlled acute and extension study of XX-XXXX in the treatment of patients with major depression”

Principal Investigator – Glaxo SmithKline Pharmaceuticals “ A 8-week, randomized, double-blind, parallel group, placebo controlled study comparing the efficacy and safety of XXXXXXXXXXXX or paroxetine or placebo in moderately to severely depressed patients with major depression”

Principal Investigator – Eli Lilly and Company, “ XXXXXXXXXXXX vs. placebo in the treatment of elderly patients with major depression”

Principal Investigator - Glaxo SmithKline Pharmaceuticals “ A Multi-Center, Double-Blind, Placebo Controlled, Study Evaluating Efficacy, Safety, and Tolerability of Once Daily dosing of XXXXXXXXXXXX (XXmg-XXmg-XXmg) versus Placebo in subjects with Major Depression over an Eight Week period”

Principal Investigator – Wyeth-Ayerst Pharmaceuticals, “ Long Term Response and Relapse Prevention Study of Major Depression, comparing XXXXXXXXXXXX-XR vs. fluoxetine, in patients over 18 years of age”

Principal Investigator – Pfizer Pharmaceuticals, Protocol “ A 6 Week, Double Blind Study of Generalized Anxiety Disorder with XXXXXXXXXXXX in Adults age 18 years and older”

Principal Investigator -“ A 8 Week, Double Blind Study of Panic Disorder with XXXXXXXXXXXX in Adults age 18 years and older”, Pfizer Pharmaceuticals, Protocol

Principal Investigator – GlaxoSmithKline Pharmaceuticals, Protocol Number XXXXXX-XXX “A 6 Week Double Blind Study of XXXXXXXXXXXX-CR in the Treatment of Out-patient Major Depression with Anxiety”

Principal Investigator – Sepracor Pharmaceutical, Protocol XXXX-XXX “ Double blind study of Primary Insomnia in the Elderly (65 years and older) population utilizing XXXXXXXXXXXX, a 2 Week study”

Principal Investigator – Sepracor Pharmaceuticals, Protocol XXXX-XXX “Double Blind study in Primary Insomnia utilizing XXXXXXXXXXXX in short and long term adult (age 18-64) population”

Principal Investigator-Wyeth-Ayerst Pharmaceuticals, Protocol XXXX-XXX “Short Term Study of XXXXXXXXXXXX XR In Childhood and Adolescent Generalized Anxiety Disorder”. A Double blind study, placebo controlled, 8 week study

Principal Investigator-Parke-Davis Protocol XXXX-XXX, “A Sustained Efficacy Study of XXXX in Patients with Social Phobia”

Principal Investigator-SmithKline Beechem Pharmaceuticals, Protocol XXX-XX-XXXX, “R-XXXXXX Versus Placebo in the Treatment of Major Depression”

Principal Investigator-SmithKline Beecham Pharmaceuticals Protocol XXXXX/XXX, “Randomized Multi-Center, 8-Week, Double Blind, Placebo-Controlled Flexible Dose Study to Evaluate the Efficacy and Safety of XXXXX in Children and Adolescents with Major Depression Disorder”

“A Phase II Open-Label Safety and Efficacy Study of XXXXX in Outpatients with ADHD 6 to 18 years”, Principal Investigator-Protocol Eli Lilly & Co. Protocol Number XXX\XX-XXXX-

Principal Investigator-SmithKline Beecham Protocol XXXXX/XXX, “A 16 Week Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Tolerability of XXXXX in the Treatment of Children and Adolescents with Social Anxiety Disorder/Social Phobia”

Principal Investigator-Eli Lilly Protocol Number XXX-XX-XXXX, “Long-Term Open-Label Treatment with R-XXXX Hydrochloride for Evaluation of Safety”

Principal Investigator- Eli Lilly & Co. Protocol XXX-XX-XXXX, “R-XXXX Versus Placebo in the Treatment of Generalized Anxiety Disorder”

Principal Investigator-SmithKline Beecham Pharmaceuticals Protocol Number XXXXX-XXX, “A Double-blind, Placebo-controlled, 3-arm fixed dose study of XXXX CR Continuous Treatment (12.5mg and 25mg/day) for Premenstrual Dysphoric Disorder”

Principal Investigator-SmithKline Beecham Pharmaceuticals Protocol XXXXX-XXX, “A Randomized, Multicenter, 10-week, Double Blind, Placebo-Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of XXXXX in Children and Adolescents with Obsessive-Compulsive Disorder (ODC)”

Principal Investigator-Parke-Davis Protocol XXXX-XXX, “A Sustained Efficacy Study of XXXXX in Patients with Generalized Anxiety Disorder”

Principal Investigator-Parke-Davis Protocol XXXXX-XXX, “A Placebo-Controlled Study of XXXXX and XXXXX in Patients with Panic Disorder”

Principal Investigator-Somerset Protocol XXXXXX-XXXXX, “A Double-Blind, Placebo-Controlled, Parallel-Group Assessment of the XXXXXX Tran dermal System in the Prevention of Relapse of Symptoms Associated with Major Depression”

Principal Investigator-R.W. Johnson Pharmaceutical Research Institute-Protocol Topmat-XXXX-XXX, “Open-Label Extension Study of the Safety and Tolerability of XXXX in Subjects with Bipolar I Disorder Who Completed Protocol Topmat-XXXX-XXX(Rwj-XXXXX)”

Principal Investigator-R.W. Johnson Pharmaceutical Research Institute-Protocol XXXXXX-Pdmd-XXX, “Placebo-Controlled Study of the Safety and Efficacy of Rwj-xxxxx in the Treatment of Acute Manic or Mixed episodes in Subjects with Bipolar 1 Disorder”

Principal Investigator-Smith Kline Beecham Pharmaceuticals Protocol Number XXXXX-XXX “A 8 Week, Double-Blind, Fixed Dose Comparison of 20 and 40 mg Daily of XXXXX and Placebo in Patients Suffering from Posttraumatic Stress Disorder (PTSD)

Principal Investigator-Hoffman LaRouche Protodigm/Xenical Protocol #XXXXXX-XXXX, “A Double-Blind Randomized Comparison of the Efficacy and Safety of 52 Weeks of XXXXX™ Therapy Plus Diet in the Treatment of Obesity in Peri and Post-Menopausal Women at Cardiovascular Risk”

Principal Investigator-Smith Kline Beecham Pharmaceuticals Protocol XXXXXX/XXX, “A Double Blind, Placebo Controlled, Flexible Dosing Trial to Evaluate the Efficacy of Modified Release XXXXX In the Treatment of Panic Disorder”

Sub-Investigator-Smith Kline Beecham Pharmaceuticals Protocol Number XXXXX/XXX, “A Double-Blind Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release XXXXX and modified Release XXXXX In the Treatment of Major Depression”